CorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update

Conference Call and Webcast to be held Friday, March 17, 2017, at 8:30 a.m. Eastern Time

Bedminster, NJ – March 10, 2016 – CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it will issue its financial results for the fourth quarter ended December 31, 2016, after the market close on Thursday, March 16, 2017.

CorMedix CEO, Khoso Baluch will host a conference call and webcast on Friday, March 17, 2017, at 8:30 AM Eastern Time to discuss recent corporate developments and financial results.

Dial-In (Toll Free)                   877-407-8031
International Dial-In              201-689-8031

The live audio webcast will be accessible via the Events section of the CorMedix website.

A replay of the teleconference will be available until 11:59 p.m. on March 24, 2017.

Replay Number:                      877-481-4010
Replay International:             919-882-2331
Conference ID:                        10273

About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease. The Company is focused on developing its lead product Neutrolin^®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical study in patients undergoing chronic hemodialysis via a central venous catheter. The company is planning to conduct its second Phase 3 study in patients with cancer receiving IV parenteral nutrition, chemotherapy and hydration via a chronic central venous catheter, subject to sufficient resources. If successful, the two pivotal studies may be submitted to the FDA for potential approval for both patient populations. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to potentially accelerated FDA review and up to 10 years of market exclusivity upon potential U.S. approval. It is already a CE Marked product in Europe and other territories. CorMedix is also seeking to unlock additional value for its taurolidine-based technology by establishing collaborative partnerships in oncology and medical device applications. For more information visit: www.cormedix.com.

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150